AI
MYGN icon

Atria Investments’s Myriad Genetics MYGN Stock Holding History

Atria Investments’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,676
Closed -$94.7K – 2048
2025
Q1 		$94.7K Buy
+10,676
New +$128K ﹤0.01% 1875
2024
Q4 		– Sell
-11,414
Closed -$313K – 1938
2024
Q3 		$313K Buy
11,414
+581
+5% +$15.7K ﹤0.01% 1604
2024
Q2 		$265K Buy
+10,833
New +$238K ﹤0.01% 1661
2014
Q3 		– Sell
-53,944
Closed -$2.1M – 474
2014
Q2 		$2.1M Buy
+53,944
New +$2.01M 0.21% 96

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Atria Investments's MYGN Position: Q2 2025 in Review

Atria Investments sold out of Myriad Genetics (MYGN) in Q2 2025, closing a stake of 10,676 shares — an estimated $94.7K sold.

Atria Investments first reported a position in MYGN in Q2 2014 and held it in 4 quarters. The position peaked at $2.1M in Q2 2014. 221 funds tracked by Wall St. Rank hold MYGN as of Q2 2025.

  • Atria Investments reported no remaining Myriad Genetics position as of Q2 2025 after selling out during the quarter.
  • Atria Investments sold 10,676 Myriad Genetics shares in Q2 2025, an estimated $94.7K.
  • Atria Investments first reported a position in Myriad Genetics in Q2 2014 and held it in 4 quarters.
  • Atria Investments's Myriad Genetics position peaked at $2.1M in Q2 2014.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2025.

Based on Atria Investments's 13F filing for Q2 2025, filed 4 Aug 2025.